-
Recent indications that the Trump administration is seeking to slash approximately $5.8 billion from the National Institutes of Health budget has touched off debate about public versus private medical research and the impact those budget cuts could have on the development of new therapies and medicines to treat patients.
-
Democratic candidate Hillary Clinton announced in late September that she would demand a stop to excessive profiteering and marketing costs by encouraging innovation and new treatments from drug companies — including a stop to direct-to-consumer drug company advertising subsidies — and reinvesting funds in research.
-
Dr. Scott Gottlieb recently spoke to the International Society for Stem Cell Research in Berkeley, California, to address how the FDA needs to adapt its approach to pre-market regulations of novel areas of technology -- such as gene therapy -- focusing on measures of risk rather than clinical applications.
-
Recent discussions about the antiquities of Medicare and how it is shaping the future of health care have been heating up, especially with respect to Obamacare reform and Medicare’s place within the system. The American Enterprise Institute (AEI) is one organization that has called for Medicare reform, emphasizing its importance.